TIDMAMC

RNS Number : 9466S

Amur Minerals Corporation

14 March 2023

14 March 2023

Amur Minerals Corporation

("Amur" or the "Company")

Receipt of Funds

Amur Minerals Corporation ("Amur" or the "Company"), is pleased to confirm it is in receipt of the agreed consideration, an amount of US$35 million, for the sale of the Company's 100% interest in its nickel - copper sulphide asset, Kun-Manie, located in the Russian Federation.

The Company has previously announced that it will pay a special dividend of 1.8 pence per share to shareholders within 90 days of the receipt of funds. Further announcements in respect of the dividend dates will be made in due course.

Following the disposal of Kun-Manie on 06 March 2023, Amur Minerals became an AIM Rule 15 cash shell and accordingly, is required to make an acquisition or acquisitions which constitute(s) a reverse takeover under AIM Rule 14 on or before the date falling six months from the completion of the disposal, or be re-admitted to trading on AIM as an investing company under AIM Rule 8. Failing that, the Company's ordinary shares would be suspended from trading on AIM pursuant to AIM Rule 40. If the Company's shares remain suspended for six months, admission of the Company's shares will be cancelled.

For further information, and Company updates see the Company website at www.amurminerals.com twitter page @ amur_minerals.

Market Abuse Regulation (MAR) Disclosure

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

Enquiries:

 
       Company            Nomad and Broker        Public Relations 
  Amur Minerals Corp.    S.P. Angel Corporate         BlytheRay 
                             Finance LLP 
   Robin Young CEO        Richard Morrison           Megan Ray 
                              Adam Cowl              Tim Blythe 
                           +44 (0) 20 3470 
  +1 (925) 408-4621              0470           +44 (0) 20 7138 3204

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCFLFSFVSISLIV

(END) Dow Jones Newswires

March 14, 2023 09:00 ET (13:00 GMT)

Crism Therapeutics (AQSE:AMC.GB)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Crism Therapeutics.
Crism Therapeutics (AQSE:AMC.GB)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Crism Therapeutics.